Bank of New Hampshire’s Biogen BIIB Stock Holding History

Bank of New Hampshire’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.32K	Hold	20	–	–	﹤0.01%	497
2026 Q1	$3.67K	Buy	+20	New	+$3.69K	﹤0.01%	504

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Bank of New Hampshire's BIIB Position: Q2 2026 in Review

Bank of New Hampshire held its Biogen (BIIB) position steady in Q2 2026 at 20 shares worth $4.32K. The position accounts for ﹤0.01% of the portfolio, ranked #497.

Bank of New Hampshire first reported a position in BIIB in Q1 2026 and has held it in 2 quarters since. 569 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Bank of New Hampshire held 20 shares of Biogen worth $4.32K as of Q2 2026.
Bank of New Hampshire left its Biogen share count unchanged in Q2 2026.
Biogen made up ﹤0.01% of Bank of New Hampshire's portfolio in Q2 2026, its #497 holding.
Bank of New Hampshire first reported a position in Biogen in Q1 2026 and has held it in 2 quarters since.
569 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Bank of New Hampshire's 13F filing for Q2 2026, filed 14 Jul 2026.